How much revenue does Nunzia Pharmaceutical make?

Nunzia Pharmaceutical reported $0 in revenue for fiscal year 2021. In Q3 2022 revenue was $0.

What companies are similar to Nunzia Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include MultiCell Technologies, Inc. (MCET), Creative Edge Nutrition, Inc. (FITX), CannLabs, Inc. (CANL), Vitalibis, Inc. (VCBD).

Nunzia Pharmaceutical Company (NUNZ) Stock

About Nunzia Pharmaceutical Company

Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Comp...

At a glance

Nunzia Pharmaceutical reported revenue of $0 for fiscal year 2021, and net income of -$78.06 million. In Q3 2022 (the quarter ended September 30, 2022) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2021.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.